INNOCAN PHARMA Corp (INNPF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
INNOCAN PHARMA Corp (INNPF) trades at $1.60 with AI Score 61/100 (Grade B+). InnoCan Pharma Corporation is a Canadian pharmaceutical company specializing in the development of CBD-integrated drug delivery platforms, including exosomes and liposomes, for various medical conditions. Market cap: $7.20M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for INNPF: INNPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INNPF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
INNPF: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →INNOCAN PHARMA Corp (INNPF) Healthcare & Pipeline Overview
InnoCan Pharma Corporation is a Canadian pharmaceutical company specializing in the development of CBD-integrated drug delivery platforms, including exosomes and liposomes, for various medical conditions. The company also commercializes branded CBD topical products, operating across the United States, Poland, France, and other international markets, focusing on innovative cannabinoid-based therapeutic solutions.
What Is the Investment Thesis for INNPF?
InnoCan Pharma Corporation's investment profile is characterized by its strategic focus on developing proprietary cannabidiol (CBD) loaded drug delivery platforms, specifically exosomes and liposomes, which represent a significant long-term growth catalyst within the pharmaceutical sector. The company's research and development initiatives, including the exploration of CBD-loaded exosomes for conditions like COVID-19, position it at the forefront of innovative cannabinoid-based therapeutics. This R&D-intensive approach, while contributing to a current profit margin of -6.0%, is balanced by an exceptionally high gross margin of 89.8% on its commercialized topical products, indicating strong unit economics for its existing market offerings. The ongoing commercialization of branded CBD topical treatments across the United States, Poland, and France provides immediate revenue and market presence. Future value drivers include successful clinical advancements of its drug delivery platforms, potential licensing agreements, and expansion into new therapeutic areas and geographic markets. The company's relatively small market capitalization of $7.20M suggests potential for substantial appreciation upon key R&D milestones or market penetration.
Based on FMP financials and quantitative analysis
INNPF Key Highlights
- Market Capitalization: $0.02 billion, reflecting its status as a small-cap pharmaceutical company.
- Profit Margin: -6.0%, indicative of significant investment in research and development activities.
- Gross Margin: 89.8%, demonstrating strong profitability on its commercialized product sales.
- Beta: -0.25, suggesting low correlation with broader market movements, potentially due to its specific niche and OTC listing.
- Employee Base: 11 employees, highlighting a lean operational structure focused on specialized R&D and commercialization.
Who Are INNPF's Competitors?
INNPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| NPNKF Nippon Shinyaku Co., Ltd. | $32.75 | +4.30% | $2.21B | 61 |
| ETST Earth Science Tech, Inc. | $0.17 | +25.56% | $48.85M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
| ESALF Eisai Co., Ltd. | $25.00 | +0.00% | $7.05B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INNPF's Key Strengths?
- Proprietary R&D focus on advanced CBD drug delivery platforms (exosomes, liposomes).
- High gross margin (89.8%) on existing commercial products.
- Diversified product portfolio including both R&D pipeline and commercial topical treatments.
- International market presence in key regions like the US, Poland, and France.
What Are INNPF's Weaknesses?
- Ongoing negative profit margin (-6.0%) due to R&D investments.
- Small employee base (11) potentially limiting scale and rapid expansion.
- Trades on OTC markets, which can imply lower liquidity and transparency compared to major exchanges.
- Relatively small market capitalization ($0.02 billion), indicating early-stage company status.
What Could Drive INNPF Stock Higher?
- Positive preclinical or clinical trial results for CBD loaded exosome or liposome drug delivery platforms.
- Expansion of commercial product distribution into new international markets, increasing sales reach.
- Introduction of new branded CBD topical products, diversifying the existing commercial portfolio.
- Continued research and development efforts into novel CBD-based therapeutic applications.
- Formation of strategic partnerships or licensing agreements for its proprietary drug delivery technologies.
What Are the Key Risks for INNPF?
- Financial-distress signal — its Altman Z-Score of -0.29 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-31.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant R&D expenditure contributing to a negative profit margin, requiring sustained funding.
- Failure of preclinical or clinical trials for its CBD loaded exosome and liposome platforms, impacting future drug development.
- Regulatory hurdles and evolving legal frameworks surrounding CBD products and cannabinoid-based pharmaceuticals in various operating regions.
- Intense competition from larger pharmaceutical companies and other biotech firms in the rapidly growing cannabinoid therapeutics market.
- Challenges associated with trading on the "OTC Other" market, including low liquidity and limited public disclosure.
What Are the Growth Opportunities for INNPF?
- Advancement of CBD Loaded Exosomes Platform: InnoCan's research into CBD loaded exosomes for conditions like COVID-19 represents a significant growth opportunity. Exosomes offer a promising drug delivery mechanism due to their natural ability to transfer biomolecules and target specific cells, potentially enhancing CBD's therapeutic efficacy and reducing side effects. The global exosome therapeutics market is projected to grow substantially, with estimates reaching billions of dollars in the coming decade. Successful preclinical and clinical development of this platform could lead to breakthrough treatments, attracting partnerships and substantial market share in the advanced drug delivery segment.
- Development of CBD Loaded Liposomes: The company's focus on CBD loaded liposomes provides another avenue for growth. Liposomes are well-established drug delivery vehicles known for improving drug solubility, stability, and targeted delivery. By encapsulating CBD within liposomes, InnoCan aims to optimize its pharmacokinetic profile and therapeutic effects for various conditions. The global liposome drug delivery market is a multi-billion dollar industry, continuously expanding with new applications. Successful formulation and clinical validation of CBD liposomes could open doors to a wide range of pharmaceutical products, enhancing InnoCan's intellectual property and market reach.
- Geographic Market Expansion for Commercial Products: InnoCan Pharma currently commercializes its branded CBD topical products in the United States, Poland, and France, among other international markets. A key growth opportunity lies in expanding the distribution and sales network for these products into new, underserved, or rapidly growing international markets. The global CBD market is projected to reach tens of billions of dollars by the end of the decade, with significant growth potential in regions with evolving regulatory frameworks. Strategic partnerships and targeted marketing efforts in new territories could substantially increase revenue from its existing commercial portfolio.
- Expansion into New Therapeutic Indications: While InnoCan's R&D currently includes COVID-19 treatment using CBD loaded exosomes, there is vast potential to explore additional therapeutic indications for its proprietary CBD delivery platforms. Cannabinoids are being investigated for a wide array of conditions, including chronic pain, neurological disorders, inflammatory diseases, and dermatological issues. Expanding research into these areas, supported by preclinical data, could unlock new, high-value pharmaceutical markets. Each successful new indication could represent a multi-billion dollar market opportunity, diversifying InnoCan's pipeline and reducing reliance on a single therapeutic focus.
- Strategic Partnerships and Licensing Agreements: Given InnoCan's specialized focus on CBD drug delivery platforms, a significant growth opportunity lies in forming strategic partnerships with larger pharmaceutical companies or licensing its proprietary technologies. Such collaborations could provide crucial funding for advanced clinical trials, leverage established distribution networks, and accelerate market penetration for its drug candidates. Licensing agreements for its exosome or liposome technologies could generate substantial upfront payments and royalty streams, validating its R&D efforts and providing non-dilutive capital for further development. This strategy could significantly de-risk its R&D investments and broaden its impact.
What Opportunities Does INNPF Have?
- Expanding global market for CBD and cannabinoid-based therapeutics.
- Potential for new therapeutic indications for its drug delivery platforms beyond current R&D.
- Strategic partnerships and licensing agreements to accelerate development and commercialization.
- Geographic expansion into new international markets for existing commercial products.
What Threats Does INNPF Face?
- Regulatory changes or restrictions on CBD products and cannabinoid research.
- High risk of R&D failure for novel drug delivery platforms.
- Intense competition from larger pharmaceutical companies and specialized biotech firms.
- Funding challenges for continued research and development given the negative profit margin.
What Are INNPF's Competitive Advantages?
- Proprietary R&D in CBD loaded exosomes and liposomes, offering unique drug delivery mechanisms.
- Early-stage development in specific therapeutic applications, such as COVID-19 treatment using exosomes.
- Established portfolio of branded CBD topical products providing immediate market presence and brand recognition.
- International operational footprint, allowing for diverse market access and regulatory navigation.
- Expertise in combining pharmaceutical ingredients with CBD for enhanced efficacy and targeted delivery.
What Does INNPF Do?
InnoCan Pharma Corporation, established in 2018 and headquartered in Calgary, Canada, is a pharmaceutical company dedicated to pioneering the integration of cannabidiol (CBD) with advanced drug delivery platforms. The company's core focus revolves around developing innovative therapeutic solutions by combining CBD with other pharmaceutical ingredients, targeting a range of medical conditions. Its research and development efforts are particularly concentrated on two key drug delivery systems: CBD loaded exosomes and CBD loaded liposomes. These platforms are being investigated for their potential in treating conditions such as COVID-19, among others, aiming to enhance the efficacy and targeted delivery of CBD. Beyond its robust R&D pipeline, InnoCan Pharma is actively involved in the commercialization and sale of a diverse portfolio of branded CBD-integrated pharmaceutical and topical treatment products. This commercial segment includes a variety of consumer-facing items such as CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. These products cater to the growing demand for CBD-infused wellness and cosmetic applications, providing immediate revenue streams while the company's more complex drug delivery platforms advance through development stages. InnoCan Pharma operates with an international footprint, extending its research, development, and commercial activities across key markets including the United States, Poland, France, and other international territories. This global approach allows the company to tap into diverse regulatory environments and consumer bases, positioning itself within the evolving landscape of cannabinoid therapeutics. With a lean operational structure, managing 11 employees, InnoCan Pharma maintains a strategic focus on innovation and market expansion within the specialty and generic drug manufacturing industry, aiming to carve out a distinct niche through its proprietary CBD delivery technologies.
What Products and Services Does INNPF Offer?
- Develops drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients.
- Conducts research and development on CBD loaded exosomes for treating conditions like COVID-19.
- Engages in R&D of CBD loaded liposomes for enhanced drug delivery.
- Commercializes and sells branded CBD-integrated topical treatment products.
- Offers a range of consumer products including CBD eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and Relief & Go spray.
- Operates internationally, with activities in the United States, Poland, and France.
- Focuses on innovation within the specialty and generic drug manufacturing industry.
How Does INNPF Make Money?
- Generates revenue through the commercialization and sale of branded CBD-integrated topical treatment products directly to consumers or through retail channels.
- Aims to derive future revenue from the successful development, approval, and commercialization of its proprietary CBD loaded drug delivery platforms (exosomes and liposomes).
- Potential for licensing agreements or partnerships with larger pharmaceutical companies for its advanced drug delivery technologies, generating upfront payments and royalty streams.
- Invests significantly in research and development, with the expectation of future product launches and market penetration in the pharmaceutical sector.
What Industry Does INNPF Operate In?
InnoCan Pharma Corporation operates within the dynamic and rapidly evolving Drug Manufacturers - Specialty & Generic industry, with a specific focus on cannabinoid-based therapeutics. The broader healthcare sector is witnessing increasing interest and investment in CBD and other cannabinoids for their potential therapeutic applications. InnoCan's strategy of combining CBD with advanced drug delivery platforms, such as exosomes and liposomes, positions it within the innovative segment of this market, aiming to overcome traditional bioavailability and targeting challenges associated with cannabinoids. The competitive landscape includes both established pharmaceutical companies exploring cannabinoid derivatives and numerous smaller biotech firms specializing in cannabis-based medicines. Market trends indicate a growing acceptance and regulatory evolution for CBD products globally, particularly in wellness and medical applications. InnoCan's R&D focus on novel delivery systems could provide a differentiation point, allowing it to carve out a niche beyond the crowded topical CBD market.
Who Are INNPF's Key Customers?
- Consumers seeking CBD-integrated topical products for wellness and cosmetic applications.
- Potential pharmaceutical partners interested in licensing or collaborating on advanced CBD drug delivery platforms.
- Healthcare providers and patients, upon regulatory approval of its pharmaceutical drug candidates.
- Retailers and distributors stocking CBD wellness and cosmetic products.
ROE -32%Key Financial Metrics
Return on equity for INNOCAN PHARMA Corp stands at -31.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.24 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -18.9%, the inverse of the P/E and a quick read on earnings relative to price.
INNOCAN PHARMA Corp (INNPF) Valuation Context
Valued at $7.20M, INNPF is classified as a micro-cap stock. Relative to its peer group, INNPF's quantitative score of 61/100 is roughly in line with the peer average of 66/100.
Company Profile
INNOCAN PHARMA Corp operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Calgary, CA. The company is led by CEO Iris Bincovich. INNPF has traded publicly since 2020.
F-Score 3/9Financial Health
INNOCAN PHARMA Corp's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.29 places it in the distress zone, a signal of elevated financial risk.
INNPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary R&D focus on advanced CBD drug delivery platforms (exosomes, liposomes).
- High gross margin (89.8%) on existing commercial products.
- Diversified product portfolio including both R&D pipeline and commercial topical treatments.
- International market presence in key regions like the US, Poland, and France.
Bear Case
- Ongoing negative profit margin (-6.0%) due to R&D investments.
- Small employee base (11) potentially limiting scale and rapid expansion.
- Trades on OTC markets, which can imply lower liquidity and transparency compared to major exchanges.
- Relatively small market capitalization ($0.02 billion), indicating early-stage company status.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
INNPF Latest News
-
TSX Penny Stocks With Market Caps Under CA$300M To Consider
Yahoo! Finance: INNPF News · Jun 11, 2026
-
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
prnewswire.com · May 27, 2026
INNPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INNPF.
Price Targets
Wall Street price target analysis for INNPF.
INNPF MoonshotScore
What does this score mean?
The MoonshotScore rates INNPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Iris Bincovich
Chief Executive Officer
Unknown. Information regarding Iris Bincovich's specific career history, educational background, or previous roles prior to her current position at InnoCan Pharma Corporation is not provided in the source data.
Track Record: Unknown. Specific achievements, strategic decisions, or company milestones directly attributable to Iris Bincovich's leadership at InnoCan Pharma Corporation are not detailed in the provided source information.
INNPF OTC Market Information
InnoCan Pharma Corporation trades on the "OTC Other" tier of the OTC Markets. This tier is for companies that do not meet the disclosure requirements of OTCQX or OTCQB, or that are not eligible for the Pink Open Market. Unlike major exchanges like NYSE or NASDAQ which have stringent listing requirements for financial health, corporate governance, and minimum share price, "OTC Other" has minimal to no ongoing disclosure requirements. This contrasts sharply with the higher OTC tiers (OTCQX, OTCQB) which require audited financials and regular reporting, or even the Pink Open Market which may have some disclosure.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure, making it difficult to assess financial health and operational performance.
- Low trading liquidity, leading to wide bid-ask spreads and potential difficulty in exiting positions.
- Increased susceptibility to fraud and manipulation due to less regulatory oversight.
- Difficulty in obtaining reliable and timely information for informed investment decisions.
- Potential for significant price volatility due to thin trading volumes and speculative interest.
- Verify the company's current financial statements and audit reports, if any are available.
- Research all available public filings and news releases, even if disclosure is "Unknown."
- Assess the management team's background and track record through independent sources.
- Evaluate the company's business model, products, and market potential thoroughly.
- Understand the regulatory environment for CBD and pharmaceutical development in its operating regions.
- Scrutinize the company's capital structure and shareholder base.
- Consider the potential for dilution from future capital raises.
- Active research and development into specific drug delivery platforms (exosomes, liposomes).
- Commercialization of branded CBD topical products, indicating existing revenue streams.
- International operations in multiple countries (US, Poland, France), suggesting broader market engagement.
- Incorporated in 2018, indicating a relatively established presence in the sector.
- Focus on a specific and evolving niche within the pharmaceutical industry (CBD integration).
What Investors Ask About INNOCAN PHARMA Corp (INNPF) — Healthcare
What does INNOCAN PHARMA Corp do?
InnoCan Pharma Corporation is a pharmaceutical company focused on developing advanced drug delivery platforms that integrate cannabidiol (CBD) with other pharmaceutical ingredients. The company's core R&D efforts are centered on CBD loaded exosomes and CBD loaded liposomes, exploring their potential for treating various conditions, including COVID-19. Concurrently, InnoCan commercializes and sells a range of branded CBD-integrated topical treatment products, such as eye serums, face oils, and recovery lotions. Operating internationally across the United States, Poland, and France, InnoCan aims to leverage innovative cannabinoid science to create both pharmaceutical solutions and consumer wellness products within the specialty and generic drug manufacturing industry.
What are the key growth opportunities for INNPF in healthcare?
InnoCan Pharma's primary growth opportunities in the healthcare sector stem from the advancement and commercialization of its proprietary CBD loaded drug delivery platforms. The successful development and clinical validation of its exosome and liposome technologies, particularly for novel therapeutic indications beyond current research, could unlock significant market potential. Expanding the geographic reach of its existing branded CBD topical products into new international markets represents another immediate growth driver. Furthermore, forming strategic partnerships or licensing agreements with larger pharmaceutical entities could provide essential funding, accelerate product development, and broaden market access, thereby enhancing InnoCan's position in the evolving cannabinoid therapeutics landscape.
What are the main risks for INNPF?
InnoCan Pharma faces several notable risks, primarily associated with its R&D-intensive business model. A significant ongoing risk is the negative profit margin of -6.0%, indicating that the company is currently not profitable, largely due to investments in research and development. There is a potential for clinical trial failures for its novel CBD loaded exosome and liposome platforms, which could severely impact its long-term pharmaceutical prospects. Regulatory uncertainty and evolving legal frameworks for CBD products across its international operating regions pose an ongoing threat. Additionally, the company operates in a highly competitive market, and its status on the "OTC Other" market tier presents risks related to limited disclosure and low trading liquidity.
What revenue streams does INNOCAN PHARMA Corp have in healthcare?
InnoCan Pharma Corporation primarily generates revenue through the commercialization and sale of its branded CBD-integrated topical treatment products. These products, which include items like CBD eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray, are sold to consumers in markets such as the United States, Poland, and France. While the company has a strong gross margin of 89.8% on these sales, indicating efficient production and pricing, its overall profit margin is negative due to significant R&D investments. Future revenue streams are anticipated from the successful development, regulatory approval, and potential licensing or direct commercialization of its advanced CBD loaded exosome and liposome drug delivery platforms.
What are the key factors to evaluate for INNPF?
INNOCAN PHARMA Corp (INNPF) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does INNPF data refresh on this page?
INNPF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven INNPF's recent stock price performance?
INNOCAN PHARMA Corp (INNPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary R&D focus on advanced CBD drug delivery platforms (exosomes, liposomes). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INNPF overvalued or undervalued right now?
Valuing INNOCAN PHARMA Corp (INNPF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding CEO's detailed background and track record was not provided in the source data and is marked as 'Unknown'.
- No FMP PEER TICKERS were provided in the source data, hence the 'competitors' array is empty.
- Disclosure status for OTC trading is explicitly stated as 'Unknown' in the source data.